Migraine treatment and placebo effect

被引:14
作者
Speciali, Jose G. [1 ]
Peres, Mario [2 ]
Bigal, Marcelo E. [3 ,4 ]
机构
[1] Univ Sao Paulo, Dept Neurol, Sch Med Ribeirao Preto, Sao Paulo, Brazil
[2] Albert Einstein Med Hosp, Div Neurol, Sao Paulo, Brazil
[3] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[4] Merck Res Labs, Whitehouse Stn, NJ USA
关键词
acute treatment; migraine; placebo; placebo effect; preventive treatment; BLIND CLINICAL-TRIALS; TOXIN TYPE-A; PROPHYLACTIC TREATMENT; PARALLEL-GROUP; MULTICENTER; HEADACHE; ACUPUNCTURE; MECHANISMS; ANALGESIA; EFFICACY;
D O I
10.1586/ERN.10.8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Placebos are typically defined as physiologically inactive substances that elicit a therapeutic response. The antipode of the placebo effect is the nocebo effect, or the negative effects of placebo, where unpleasant symptoms (e.g., adverse events) emerge after the administration of placebo. Placebo analgesia is one of the most striking examples of the cognitive modulation of pain perception. Herein we focus on the importance of placebo in headache research. We first review the mechanisms of the placebo effect. We then focus on the importance of placebo in the acute treatment of migraine. We follow by discussing the importance of placebo on the preventive treatment of migraine and our perspectives for the 5 years to come regarding the study of the placebos.
引用
收藏
页码:413 / 419
页数:7
相关论文
共 50 条
[21]   Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data [J].
Dodick, David W. ;
Silberstein, Stephen D. ;
Lipton, Richard B. ;
DeGryse, Ronald E. ;
Adams, Aubrey Manack ;
Diener, Hans-Christoph .
CEPHALALGIA, 2019, 39 (08) :945-956
[22]   Cyproheptadine Treatment in Children and Adolescents with Migraine: A Retrospective Study in Japan [J].
Shimomura, Hideki ;
Tokunaga, Sachi ;
Terasaki, Eisuke ;
Taniguchi, Naoko ;
Taniguchi, Yohei ;
Yoshitake, Saeka ;
Terakita, Yuki ;
Inoue, Kenji ;
Okuda, Masumi ;
Kato, Takeo ;
Takeshima, Yasuhiro .
NEUROLOGY INTERNATIONAL, 2024, 16 (06) :1308-1317
[23]   Recognition and treatment of menstrual migraine [J].
Lay, Christine L. ;
Payne, Richard .
NEUROLOGIST, 2007, 13 (04) :197-204
[24]   White matter tract microstructure of the mPFC-amygdala predicts interindividual differences in placebo response related to treatment in migraine patients [J].
Liu, Jixin ;
Mu, Junya ;
Chen, Tao ;
Zhang, Ming ;
Tian, Jie .
HUMAN BRAIN MAPPING, 2019, 40 (01) :284-292
[25]   Preventing the Progression of Episodic Migraine to Chronic Migraine with Acute Treatment Optimization [J].
Kuruvilla, Deena E. ;
Bilchik, Tanya .
CURRENT PAIN AND HEADACHE REPORTS, 2022, 26 (03) :253-258
[26]   Botulinum toxin type A in migraine prophylaxis:: Placebo effect or efficacy? [J].
Kueper, Michael ;
Diener, H. C. .
AKTUELLE NEUROLOGIE, 2007, 34 (08) :464-465
[27]   The acute and preventative treatment of episodic migraine [J].
Miller, Sarah .
ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2012, 15 :33-39
[28]   OnabotulinumtoxinA: Preventive Treatment for Chronic Migraine [J].
Chen, Shih-Pin ;
Fuh, Jong-Ling ;
Wang, Shuu-Jiun .
CURRENT PAIN AND HEADACHE REPORTS, 2011, 15 (01) :4-7
[29]   Novel synthetic treatment options for migraine [J].
Negro, Andrea ;
Martelletti, Paolo .
EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (07) :907-922
[30]   Advances in topiramate as prophylactic treatment for migraine [J].
Hu, Chuan ;
Zhang, Yixin ;
Tan, Ge .
BRAIN AND BEHAVIOR, 2021, 11 (10)